Mineralys Therapeutics, Inc. MLYS
25.86
(0.73)
(2.75%)
as of 25 Sep
- Market cap
- $2.4B
- P/E
- 0.0×
Follow MLYS
Insider Buys
alert about insiders buying in the last 12 month
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | |
|---|---|---|---|---|---|---|
Current Ratio |
43.76 | 14.02 | 23.76 | 13.98 | 2.20 | 0.29 |
Net Debt/EBITDA |
3.85 | 1.03 | 2.79 | 3.50 | 0.57 | 0.48 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.92 | 0.94 | 1.13 | 0.98 | 0.75 | 0.72 |
Capex/Depreciation |
(0.25) | (2.23) | — | — | — | — |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (36.91%) | (82.24%) | (76.13%) | 79.26% | 146.35% | 0.00% | |
| (35.65%) | (77.72%) | (39.28%) | (47.46%) | (307.79%) | 0.00% | |
ROIC |
0.00% | 0.00% | (1,153.49%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(23.93%) | (93.21%) | (30.13%) | (28.45%) | (319.84%) | 94.72% |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(2.11) | (3.43) | (2.24) | (5.66) | (2.92) | (0.53) |
Cash per Share |
9.71 | 4.08 | 6.54 | 21.31 | 2.13 | 0.30 |
Shareholders Equity per Share |
9.56 | 3.94 | 6.66 | (10.12) | (4.60) | (0.78) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
9.56 | 3.94 | 6.66 | (10.12) | (4.60) | (0.78) |
Free Cash Flow |
(142.43) | (166.41) | (81.17) | (29.22) | (14.56) | (2.46) |
Working Capital |
646.27 | 190.71 | 238.62 | 104.74 | 6.07 | (3.62) |
Capital Expenditures |
(0.01) | (0.10) | — | — | — | — |
Net Current Asset Value |
646.27 | 190.71 | 238.62 | (53.90) | (22.93) | (3.62) |
| Other line items | ||||||
Quick Ratio |
43.45 | 13.53 | 22.57 | 13.65 | 2.10 | 0.28 |
Depreciation/Fixed assets |
1.55 | 0.81 | — | — | — | — |
Cash ROIC |
(10.93%) | (42.72%) | (16.99%) | (50.52%) | 118.24% | 112.57% |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(2.10) | (3.43) | (2.24) | (5.66) | (2.92) | (0.53) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
1.25 | 0.54 | 1.25 | 1.34 | 0.65 | — |
Average Assets |
433.85 | 228.77 | 183.04 | 62.78 | 6.31 | — |
Average Common Equity |
418.98 | 216.21 | 94.44 | (37.60) | (13.26) | — |
Capex to Sales |
0.00 | 0.00 | — | — | — | — |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates